The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Abbott Laboratories beat expectations on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue increased and GAAP earnings per share dropped significantly.
Margins dropped across the board.
Abbott Laboratories logged revenue of $10.84 billion. The seven analysts polled by S&P Capital IQ predicted net sales of $10.61 billion on the same basis. GAAP reported sales were 4.4% higher than the prior-year quarter's $10.38 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $1.51. The nine earnings estimates compiled by S&P Capital IQ predicted $1.50 per share. GAAP EPS of $0.66 for Q4 were 35% lower than the prior-year quarter's $1.02 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 62.5%, 50 basis points worse than the prior-year quarter. Operating margin was 22.5%, 70 basis points worse than the prior-year quarter. Net margin was 9.7%, 590 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $5.55 billion. On the bottom line, the average EPS estimate is $0.46.
Next year's average estimate for revenue is $22.97 billion. The average EPS estimate is $1.95.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 2,546 members out of 2,636 rating the stock outperform, and 90 members rating it underperform. Among 661 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 642 give Abbott Laboratories a green thumbs-up, and 19 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Abbott Laboratories is hold, with an average price target of $71.03.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Abbott Laboratories. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add Abbott Laboratories to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.